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Gastric cancer is one of the leading types of cancer worldwide.
Although the trend in death rates for gastric cancer is decreasing,
prognosis is poor and few therapeutic options are available,
particularly in advanced stages. The frequency of HER2-positive
gastric cancer is 22.1% based on ToGA trial. Although reports are
conflicting, some studies have suggested that HER2-positive status in
gastric cancer is associated with poor outcomes and aggressive
disease. Trastuzumab, trade name HERCEPTIN, is a HER2-targeting
therapeutic antibody and approved for the treatment of
HER2-overexpressing breast cancer. Currently, trastuzumab is also
approved for the treatment of HER2-overexpressing metastatic gastric
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cancer based on ToGA trial that proved the clinical benefit of
combination treatment of trastuzumab and chemotherapy. Median
overall survival was 13.8 months in trastuzumab plus chemotherapy
compared with 11.1 months in those assigned to chemotherapy alone.
Nonetheless, improving therapeutic efficacy and patient survival is
important, particularly in patients with HER2-positive gastric cancer.
Recent evidence suggests that particular combinations of non
competing antibodies targeting the same receptor increase antitumor
activity in vitro and in vivo. One example is the combination of
pertuzumab, which binds to sub-domain II of the extracellular domain
(ECD) of HER2, with trastuzumab, which binds to sub-domain IV.
Pertuzumab, which has limited antitumor activity as a single agent in
HER2-overexpressing breast cancer cells, shows increased efficacy in
combination with trastuzumab. The increased efficacy of antibody
combinations has also been demonstrated with EGFR-targeting or
VEGFR3-targeting antibodies.
In this thesis, I have investigated on the efficacy and mechanism of a
novel HER2-targeting monoclonal antibody 1E11 in HER2-positive
gastric and breast cancer. 1E11 shows significant antitumor activity
as a single agent in in vitro and in vivo HER2-positive gastric
cancer models. Antitumor activity of 1E11 is increased in a highly
synergistic manner in combination with trastuzumab. The two
antibodies bind to sub-domain IV of the receptor, but have
non-overlapping epitopes, allowing them to simultaneously bind to
HER2. Treatment with 1E11 alone induced apoptosis in HER2-positive
cancer cells, and this effect was enhanced by combination treatment
with trastuzumab. Combination treatment with 1E11 and trastuzumab
reduced the levels of total HER2 protein and those of aberrant HER2
signaling molecules including phosphorylated HER3 and EGFR. Since
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1E11 is murine-derived monoclonal antibodies, murine variable region
could be immunogenic in human. So I performed humanization by
CDR-grafting of murine CDRs of 1E11 to human antibody germline
framework. The humanized antibody by this approach, hz1E11, shows
almost identical affinity and biological activity to the parental
antibody. To improve the affinity of hz1E11, I performed affinity
maturation by site-directed mutagenesis in CDR3 of heavy and light
chain. Using antibody phage display technology, I selected 1A12 clone
which has 4 amino acid mutations in CDR-L4 and shows improved
affinity more than 10-fold. I confirmed that antitumor activity of
1A12 is correlated with HER2 levels in more than 15 gastric and
breast cancer cell panels. The antibody-dependent cellular cytotoxicity
(ADCC) activity of 1A12 is comparable to that of trastuzumab and
pertuzumab. In combination setting with trastuzumab, 1E11 completely
inhibits tumor growth in OE-19 xenograft model, while pertuzumab
causes partial inhibition of tumor growth.
In conclusion, 1E11 showed synergistic antitumor activity in
combination with trastuzumab in HER2-positive human gastric cancer
in vitro and in vivo. The antitumor activity of 1E11 was mediated by
its apoptotic activity and the inhibition of HER2 homo-and
hetero-dimerization downstream signaling. This antibody combination
could be a novel potent therapeutic strategy for the treatment of
patients with HER2-overexpressing gastric and breast cancer.
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BACKGROUND
1. Epidermal Growth Factor Receptor 2 (HER2) in Gastric
Cancer
Gastric cancer is one of the leading types of cancer worldwide.
Although the trend in death rates for gastric cancer is decreasing
(Siegel et al., 2012), prognosis is poor and few therapeutic options are
available, particularly in advanced stages. Since most of symptoms
for this type of cancer are nonspecific and screening strategies are
absent in some countries, most patients with gastric cancer are
developed locally advanced or metastatic disease during their illness.
The treatment for advanced gastric cancer is mainly palliative and
based on systemic chemotherapy, with median overall survival (OS)
rarely exceeding 12 months and 5-year survival rate is less than 7%
(Gomez-Martin et al., 2014 and Pasini et al., 2011). The predominant
histological type of gastric cancer is adenocarcinoma, 95% of tumors,
and the main sub-types are intestinal, diffused and mixed type.
Radical gastrectomy is the only curative treatment of gastric cancer,
but recurrences are commonly observed in approximately 60% of
patients (Buzzoni et al., 2006). For advanced stage patients,
systematic chemotherapy is the mainstay of treatment (Field et al.,
2008). Although recent studies showed some benefits from
chemotherapy regiments including docetaxel, capecitabine, irinotecan,
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cisplatin and oxaliplatin, there is no internationally accepted standard
of care (Bilici, 2014). To date, molecular targets such as epidermal
growth factor receptor (EGFR), human epidermal growth factor
receptor 2 (HER2), vascular endothelial growth factor receptor 2
(VEGFR2), and hepatocyte growth factor receptor (HGFR/c-Met)
have been tested by clinical trials in metastatic gastric cancer (Ku et
al., 2010). A recent phase III trial proved the benefit of
HER2-targeting antibody (Bang et al., 2010) and VEGFR2-targeting
antibody (Wilke et al., 2014). Despite these remarked advances with
targeted therapy, the prognosis of patients with advanced gastric
cancer remains poor. Therefore, new therapeutic options are required
to improve the survival of patients (Wagner and Moehler, 2009).
Overexpression/amplification of HER2 in breast cancer, HER2-positive
subtypes, and its relationship with very poor prognosis are well
established in breast cancer (Slamon et al., 1987 and Varley et al.,
1987). HER2-positive breast cancer is also associated with increased
risk of local growth and distinct metastasis. There are many studies
indicating that HER2 is also present in other cancers, particularly in
gastric cancer (Semba et al., 1985 and Tsuda et al., 1989).
The frequency of HER2-positive gastric cancer is 22.1% based on
ToGA trial (Bang et al., 2010). Since the examination method and
objective criteria vary between studies, the frequency of
HER2-positive gastric cancer varies in ranging from 6.0 to 29.5% in
early studies. The investigators in ToGA trial conducted a validation
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study to assess the immunohistochemistry (IHC) and fluorescence in
situ hybridization (FISH) protocols for testing HER2 status in
advanced gastric cancer (Hofmann et al., 2008). Tissue specimens
from 3,807 patients, in 24 countries, were collected and analyzed at a
central laboratory using both IHC and FISH methods and
HER2-positive gastric cancer is defined as IHC 3+ or FISH-positive
(Bang et al., 2010). There were no marked racial differences in HER2
expression; instead, differences in HER2 expression were mainly
attributed to the site of primary tumor, gastric vs. gastroesophageal
junction, and histological type. Since the IHC staining pattern of
gastric cancer is different from breast, the criteria for HER2 status
also differ between breast cancer and gastric cancer (Hofmann et al.,
2008). HER2-positive gastric cancer is defined as IHC 3+ or
FISH-positive in the USA and Japan, while it is defined as IHC 3+
or as IHC 2+ plus FISH-positive in Europe (Albarello et al., 2011).
There should be wider discussion about the algorithm and criteria to
define the HER2-positivity in gastric cancer.
Initial studies suggested a negative effect of HER2 expression level
on overall survival in gastric cancer (Okines et al., 2010 and
Yonemura et al., 1991). However, the studies in gastric cancer to date
have yielded inconsistent relationship between HER2 overexpression
and bad prognosis (Boku, 2014). Some studies showed that HER2
positivity was associated with a significantly worse prognosis (Kim
et al., 2012; Park et al., 2006; Tanner et al., 2005), whereas others
found no association between HER2 status and prognosis
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(Gomez-Martin et al., 2012 and Terashima et al., 2011). In some case,
median overall survival was longer in HER2-positive than in
HER2-negative patients (Janjigian et al., 2012 and Gomez-Martin et
al., 2012). Therefore, the relationship between HER2 status and
prognosis of gastric cancer patients remains controversial.
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Figure 1. Mechanism of homo- and hetero-dimerization of the
extracellular domain of ErbB receptors.
The unliganded extracellular region of EGFR exists as tethered and
extened, but inactive status. Ligand binding stabilizes the extended
conformation and induces homo- and/or heterodimerization. HER3
dimerization also occurs very similarly to that of EGFR. However,
HER3 could form only heterodimer because extracellular region of
HER3 does not homodimerize in solution or in cells. Extracellular
region of HER2 exists as stable extended form, so could dimerize
with other HER2 or ligand-induced EGFR or HER3.
6
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Figure 2. Downstream signaling of HER2/HER3 dimerization
HER2/HER3 dimerization by ligand, e.g., neuregulin, initiates signaling
through Ras/Raf/MEK/ERK pathway, which promotes tumor cell
survival, and the PI3K/AKT/mTOR pathway, which stimulates
proliferation. Activation of MAPK pathway leads to the transcription
of genes that drive cellular proliferation as well as migration,
differentiation and angiogenesis. Signaling through the PI3K/AKT
pathway leads to several cellular end points, and survival and
anti-apoptosis signaling are two main outcomes.
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2. HER2-Targeted Antibody Therapy
HER2 is a type 1 transmembrane receptor tyrosine kinase (RTK) and
a member of the epidermal growth factor receptor (EGFR/ErbB)
family, which includes four receptors: EGFR (HER1), c-erbB2
(HER2), c-erbB3 (HER3), and c-erbB4 (HER4). Members of EGFR
family comprise of three domains: extracellular domain corresponding
to the ligand binding site, α-helical transmembrane domain, and
intracellular domain having a tyrosine kinase activity and
phosphorylation sites (Olayioye et al., 2000). ErbB family proteins,
exception of HER2, normally folded and prevent the exposure of
extracellular sub-domain II which is key region for receptor homo-
and heterodimerization with other ErbB family receptors (Cho et al.,
2002 and Burgess et al., 2003).
The extracellular domain initiates a conformational rearrangement by
ligand binding, leading to the sub-domain II exposure (Fig. 1). The
binding of ligand seems to stabilize these receptors in a conformation
that allows dimerization (Ogiso et al., 2002). After receptor
dimerization, cross-phosphorylation of the dimer partners by tyrosine
kinase domain occurrs and docking sites are created that allow the
recruitment of downstream signaling components and the formation of
signaling complex (Mendelsohn et al., 2003). Although all four ErbB
receptors have the same essential domains, the functional activity of
each domain varies (Bagela and Swain, 2009). EGFR and ERBB4
have active tyrosine kinase domains and known ligands, however
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ERBB3 can bind to several ligands but lacks intrinsic tyrosine kinase
activity. By contrast, ERBB2 possesses an active tyrosine kinase
domain but ligand has not been identified and exists as active
conformation (Burgess et al., 2003 and Hynes and Lane, 2005). In this
active conformation, sub-domains I and III are involved in folding the
protein to expose the dimerization site so the ligand-binding site is
unavailable.
EGFR, ERBB2 and ERBB3 are all implicated in the development and
progression of cancer, however, the role of ERBB4 in oncogenesis
remains less well defined (Bagela and Swain, 2009). Among the
various homodimer and heterodimer of four receptors, the
ERBB2/ERBB3 heterodimer is considered the most potent oncogenic
signaling complex with respect to strength of interaction,
ligand-induced tyrosine phosphorylation and downstream signaling
(Holbro et al., 2003 and Pinkas-Kramarski et al., 1996). ERBB3 could
form heterodimers but not homodimers (Berger et al., 2004).
HER2 induces the transduction of signaling via two major pathways,
which are the Ras/Raf/MEK/ERK and the PI3K/AKT/mTOR
pathways (Fig. 2). These pathways promote cell proliferation,
inhibition of apoptosis, angiogenesis, and invasion, which lead to
tumor growth and progression. Activation of these signaling pathway
depends on the type of homodimers or heterodimers, and current
study suggests that HER2 homodimers could only activate
Ras/MAPK pathway, while heterodimers could activate both MAPK
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and PI3K signaling pathways (Ghosh et al., 2011). Suppression of
HER2-overexpression breast cancer by PI3K blockade proves the
importance of PI3K-mTOR signaling (Yao et al., 2009). PI3Ks are
heterodimers of a p85 regulatory subunit and p110 catalytic subunit.
Among the three human p110 isoforms (alpha, beta, and delta), the
p110 alpha catalytic subunit was recently shown to be required for
HER2-dependent mammary tumorigenesis in mice (Utermark et al.,
2012). In addition to PI3K signaling, MAPK signaling appears to
contribute to progression of HER2-positive breast cancer.
Overexpression of HER2 in estrogen receptor (ER) positive MCF-7
cells caused hyperactivation of MAPK signaling and resistance to the
ER modulator tamoxifen. Combination treatment of HER2 inhibitor
and MEK inhibitor increased tamoxifen sensitivity and suppressed
MAPK signaling in association with reduced MCF7/HER2 xenograft
tumor growth (Kurokawa et al., 2000). Since combined administration
of PI3K/mTOR inhibitor and MEK inhibitor achieved nearly complete
tumor regression in xenograft model, strategies that combine
inhibition of PI3K and MEK may achieve the most benefit against
HER2-overexpressing cancers, particularly those refractory to
HER2-targeted treatments (Roberts, et al., 2012).
Antibody-based therapy for cancer has become established over the
past 15 years and is now one of the most successful and important
strategies for treatment of patients with haematological malignancies
and solid tumors (Scott et al., 2012). The mechanism of tumor cell
killing by antibody can be summarized as direct action,
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immune-mediated action, and specific effects (Fig. 3). Antibodies
directly show antitumor activity through receptor blockade or
agonistic activity, induction of apoptosis, or delivery of a drug or
cytotoxic agent as antibody-drug conjugate (ADC). The
immune-mediated cell killing mechanisms of antibody include
complement-dependent cytotoxicity (CDC), antibody-dependent cellular
cytotoxicity (ADCC) and regulation of T cell function. Some
antibodies show antitumor activity through tumor vascular and
stromal cell ablation by vasculature receptor antagonism or ligand
trapping. The Fc function of antibodies is particularly important for
mediating tumor cell killing through ADCC and CDC.
Trastuzumab, trade name HERCEPTIN, is HER2-targeting therapeutic
antibody and approved for the treatment of HER2-overexpressing
breast cancer (Rosen et al., 2010). It is a standard-of-care treatment
for metastatic breast cancer patients with HER2-overexpressing
tumors, both as first-line treatment in combination with chemotherapy
and as a single agent in women who have HER2-overexpressing
metastatic breast cancer (MBC) that has progressed after
chemotherapy for metastatic disease (Cobleigh et al., 1999 and Slamon
et al., 2001). Currently, trastuzumab has also been approved for the
treatment of HER2-overexpressing metastatic gastric cancer based on
ToGA trial that proved the clinical benefit of combination treatment
of trastuzumab and chemotherapy (Bang et al., 2010). In ToGA trial,
594 patients were randomly assigned to trastuzumab plus
chemotherapy group (n = 298) and chemotherapy alone group (n =
13
296). Median overall survival was 13.8 months in trastuzumab plus
chemotherapy compared with 11.1 months in those assigned to
chemotherapy alone. The median progression-free survival of
trastuzumab plus chemotherapy group is 6.7 months compared 5.5
months in control group. Overall tumor response rate (47% vs. 35%),
time to progression (7.1 months vs. 5.6 months), and duration of
response (6.9 months vs. 4.8 months) were significantly improved in
the trastuzumab plus chemotherapy group.
The mechanisms of underlying the antitumor activity of trastuzumab
in HER2-positive breast cancer are not completely known, but several
have been proposed. Trastuzumab binds to extracellular sub-domain
IV of HER2 (Fig. 4), thereby inhibits ligand-independent dimerization
of the receptor and the subsequent activation of downstream signaling
(Cho et al., 2003 and Junttila et al., 2009). Trastuzumab selectively
inhibit HER2-HER3 heterodimerization and downregulates total levels
of HER2 on the cell surface, reducing PI3K and MAPK signaling
(Cuello et al., 2001 and Gajria and Chandarlapaty, 2011). Trastuzumab
has also been shown to block the HER2 protein shedding, thus,
preventing formation of the constitutively active membrane bound
p95HER2 (Molina et al., 2001). Trastuzumab also induces cell cycle
arrest by upregulation of p27kip1 and inhibition of cdk2 activity (Le et
al., 2003). Finally, HER2-positive cells are lysed through
antibody-dependent cellular cytotoxicity, ADCC (Arnould et al., 2006
and Clynes et al, 2000).
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Recent evidence suggests that particular combinations of
noncompetitive antibodies targeting the same receptor increase
antitumor activity in vitro and in vivo. One example is the
combination of pertuzumab, which binds to sub-domain II of the
extracellular domain (ECD) of HER2, with trastuzumab, which binds
to sub-domain IV (Cai et al., 2008). Pertuzumab, which has limited
antitumor activity as a single agent in HER2-overexpressing breast
cancer cells, shows increased efficacy in combination with
trastuzumab (Nahta et al., 2004). The benefits of the pertuzumab and
trastuzumab combination were further demonstrated in preclinical and
clinical trials (Baselga et al., 2010 and Scheuer et al., 2009).
Pertuzumab has been approved for the treatment of HER2-positive
metastatic breast cancer in combination with trastuzumab (Baselga et
al., 2012). Other HER2-targeting antibodies showing better efficacy in
combination than as single agents have been reported and have
shown consistent downregulation of HER2 levels and beneficial
combination effects in mouse models (Ben-Kasus et al., 2009). The
increased efficacy of antibody combinations has also been
demonstrated with EGFR-targeting antibodies (Friedman et al., 2005
and Koefoed et al., 2011).
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Figure 3. Mechanisms of antitumor activity of therapeutic
antibodies (Scott et al., 2012)
A, Direct tumor cell killing can be elicited by receptor agonist
activity leading to apoptosis (represented by the mitochondrion),
receptor antagonist activity, such as blocking dimerization and/or
kinase activation and its downstream signaling, leading to reduced
proliferation and apoptosis. An antibody binding to an enzyme can
lead to neutralization, signaling abrogation and cell death, and
conjugated antibodies can be used to deliver a payload (such as a
drug, toxin, small interfering RNA or radioisotope) to a tumor cell. B,
Immune-mediated antitumor activity can be carried out by the
induction of phagocytosis, complement-dependent cytotoxicity (CDC),
antibody-dependent cellular cytotoxicity (ADCC), genetically modified
T cells being targeted to the tumor by single-chain variable fragment
(scFv), T cells activation by antibody-mediated cross-presentation of
antigen to dendritic cells, and inhibition of T cell inhibitory receptors,
such as cytotoxic T lymphocyte-associated antigen 4 (CTLA4). C,
Vascular and stromal cell ablation can be induced by vasculature
receptor antagonism or ligand trapping (not shown), stromal cell
inhibition, delivery of a toxin to stromal cells, and delivery of a toxin
to the vasculature. MAC, membrane attack complex; MHC, major
histocompatibility complex; NK, natural killer.
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Figure 4. Epitope of trastuzumab and pertuzumab
Trastuzumab binds to sub-domain IV, whereas pertuzumab binds to
sub-domain II. Trastuzumab inhibits HER2 shedding and HER2
activation through ligand-independent HER2/HER3 dimerization. Since
pertuzumab binds to sub-domain II responsible to dimerization, it
inhibits HER2 dimerization with other ErbB family receptors. The
molecular mechanism of HER2/HER3 dimerization is not completely
known. Putative crystal structure of
HER2-ECD/trastuzumab/pertuzumab is reconstructed with
HER2-ECD/trastuzumab (PDB ID:1N8Z) and HER2-ECD/pertuzumab
(PDB ID:1S78). Sub-domain of HER2-ECD is colored to brown,
yellow, cyan, magentas for sub-domain I, II, III, and IV, respectively.





Combination of novel HER2 targeting antibody
1E11 with trastuzumab shows synergistic
antitumor activity in HER2-positive gastric cancer
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Abstract
The synergistic interaction of two antibodies targeting the same
protein could be developed as an effective anti-cancer therapy.
Human epidermal growth factor receptor 2 (HER2) is overexpressed
in 20–25% of breast and gastric cancer patients, and HER2-targeted
antibody therapy using trastuzumab is effective in many of these
patients. Nonetheless, improving therapeutic efficacy and patient
survival are important, particularly in patients with HER2-positive
gastric cancer. Here, I describe the development of 1E11, a
HER2-targeted humanized monoclonal antibody showing increased
efficacy in a highly synergistic manner in combination with
trastuzumab in the HER2-overexpressing gastric cancer cell lines
NCI-N87 and OE-19. The two antibodies bind to sub-domain IV of
the receptor, but have non-overlapping epitopes, allowing them to
simultaneously bind HER2. Treatment with 1E11 alone induced
apoptosis in HER2-positive cancer cells, and this effect was enhanced
by combination treatment with trastuzumab. Combination treatment
with 1E11 and trastuzumab reduced the levels of total HER2 proteins
and those of aberrant HER2 signaling molecules including
phosphorylated HER3 and EGFR. The synergistic antitumor activity
of 1E11 in combination with trastuzumab indicates that it could be a




Gastric cancer is one of the most common cancers, with
approximately one million new cases diagnosed each year; it is the
third leading cause of cancer death in both sexes worldwide (Ferlay
et al., 2012). Despite advances in the prevention and treatment of
gastric cancer and a decrease in mortality rates, the prognosis of
patients with gastric cancer remains poor and few effective
therapeutic options are available, in particular for advanced stages
(Siegel et al., 2012). The 5 year survival rate in most parts of the
world is approximately 20%. HER2 is a receptor tyrosine kinase and
a member of the ErbB family, which includes EGFR, HER3, and
HER4. This receptor family functions in the regulation of many
essential cellular functions such as cell proliferation, differentiation,
and apoptosis through homo- or hetero-dimerization and the
activation of signal transduction pathways (Yarden and Sliwkowski,
2001). ErbB family proteins are overexpressed in several malignancies.
In gastric cancer, overexpression of EGFR, HER2, and HER3 is
correlated with poor prognosis (Garcia et al., 2003 and Hayashi et al.,
2008). The HER2-targeting monoclonal antibody trastuzumab was
first characterized in vitro and in vivo in 1992 (Kasprzyk et al., 1992)
and was approved for the treatment of HER2-overexpressing
metastatic breast cancer in 1998. Recently, the ToGA trial
(Trastuzumab for Gastric Cancer) demonstrated the survival benefit
22
of trastuzumab in HER2-overexpressing gastric cancer patients (Bang
et al., 2010) after Food and Drug Administration approval of this
antibody for the treatment of HER2-positive metastatic gastric and
gastroesophageal junction cancer.
Recent evidence suggests that particular combinations of not
competing antibodies targeting the same receptor increase antitumor
activity in vitro and in vivo. One example is the combination of
pertuzumab, which binds to sub-domain II of the extracellular domain
(ECD) of HER2, with trastuzumab, which binds to sub-domain IV
(Cai et al., 2008 and Cho et al., 2003). Pertuzumab, which has limited
antitumor activity as a single agent in HER2-overexpressing breast
cancer cells, shows increased efficacy in combination with
trastuzumab (Nahta et al., 2004). The benefits of the pertuzumab and
trastuzumab combination were further demonstrated in preclinical and
clinical trials (Baselga et al., 2010 and Scheuer et al., 2009).
Pertuzumab has been approved for the treatment of HER2-positive
metastatic breast cancer in combination with trastuzumab (Baselga et
al., 2012). Other HER2-targeting antibodies showing better efficacy in
combination than as single agents have been reported to show
consistent downregulation of HER2 levels and beneficial combination
effects in mouse models (Ben-Kasus et al., 2009). The increased
efficacy of antibody combinations has also been demonstrated with
EGFR-targeting antibodies (Friedman et al., 2005 and Koefoed et al.,
2011).
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In the present study, I report the development of a novel
HER2-targeted antibody termed 1E11 and describe its anti-cancer
activities as a single agent and in combination with trastuzumab in
preclinical models. 1E11 had moderate efficacy in
HER2-overexpressing NCI-N87 and OE-19 gastric cancer cells;
however, its efficacy increased dramatically in vitro and in vivo when
used in combination with trastuzumab, showing a highly synergistic
effect. The binding site of 1E11 was localized to sub-domain IV, at a
distinct epitope different from that of trastuzumab. 1E11 induced
apoptosis in combination with trastuzumab, which showed weak
apoptotic activity as a single agent, and combination treatment with
1E11 and trastuzumab inhibited epidermal growth factor (EGF) and
HRG1-induced cell proliferation. The results of the present study
suggest that HER2-targeting antibody combinations are valid
therapeutic strategies for the treatment of HER2-overexpressing




Cell lines and materials
BT-474, SK-BR-3, NCI-N87, KATO-III, Hs746T, HCC-202,
HCC-1954, and MCF-7 cells were purchased from American Type
Culture Collection (ATCC). OE-19 cells were obtained from the
European Collection of Cell Culture (ECACC). MKN-7 cells were
from the Japanese Collection of Research Bioresources (JCRB), and
MKN-45, SNU-216, MDA-MB-231, and MDA-MB-453 cells were
from the Korean Cell Line Bank (KCLB). JIMT-1 cells were gifted
from Asan Medical Center in Seoul Korea. Cell culture media were
Dulbecco’s Modified Eagle’s Medium (DMEM): F-12 for BT-474 cells,
DMEM for Hs746T cells, and RPMI-1640 for all other cell lines. All
media were supplemented with 10% fetal bovine serum (FBS), and
antibiotics and cells were cultured at 37°C under 5% CO2.
Trastuzumab and pertuzumab were produced by Genentech
Incorporated, and palivizumab was produced by MedImmune, LLC.
ChromPure human IgG (Jackson Immunoresearch Lab) was used as
human IgG control antibody in in vitro assays. 1E11 and oz1E11
antibodies were produced using the 293F system (Invitrogen) and
purified using protein-A chromatography (GE Healthcare). The
oz1E11 antibody (clone name: 1A12) consists of an optimized 1E11
antibody after humanization and affinity maturation. The endotoxin
was removed with an Endotoxin removal kit (GenScript), and
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endotoxin levels were determined using an Endotoxin detection kit
(GenScript). Human HER3 and HER4 proteins were purchased from
R&D systems and rhesus HER2, mouse HER2, and rat HER2 proteins
were purchased from Sino Biological Inc.. Heregulin-1 (HRG1) and
EGF proteins were purchased from R&D systems. Other recombinant
proteins were produced as secretion proteins using the 293F system
and purified using protein-A or Ni-NTA chromatography (Qiagen
Inc.) for Fc-fused and His-fused proteins, respectively.
Cell viability assay
Cells were seeded in 96-well plates (Corning) in growth media
containing 10% FBS and pre-cultured for 24 h. The cells were
treated with antibodies at the indicated concentrations and culture for
3–6 days. For ligand-induced cell proliferation assays, NCI-N87 cells
were seeded and pre-cultured for 24 h in 0.1% FBS media and
treated with antibodies (10 mg/mL) for 1 h before the addition of
ligand (200 ng/mL). Cell proliferation was assessed 3 days after the
treatment. The WST (DoGen) or CellTiter-Glo (Promega) assay was
used to measure cell viability. Relative cell viability was calculated by
dividing the absorbance of each well by the mean absorbance of
PBS-treated wells in each plate.
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Surface Plasmon resonance (SPR) analysis
For epitope binning, trastuzumab and pertuzumab were immobilized
onto separate CM5 sensor chip surfaces (GE Healthcare) using amine
coupling at approximately 1000 response units (RU). HER2-ECD-His
(320 nM) and antibodies (1 mg/mL) were sequentially coupled by
binding for 4 min and stabilization for 5 min at 50 mL/min flow rate.
For affinity measurements, goat anti-human IgG (γ) (Invitrogen) was
immobilized onto a CM5 sensor chip using amine coupling, and
antibodies were captured at approximately 50 RU. Then,
HER2-ECD-His protein was injected at concentrations ranging from 0
to 640 nM. Sensorgrams were obtained at each concentration and
evaluated using the BIAevaluation software.
Cell cycle and apoptosis analysis
NCI-N87 and BT-474 cells were treated with 10 mg/mL of antibodies
in complete growth media. After 2 days of antibody treatment, cells
were detached with trypsin and 1 × 105 cells were used for analysis.
For cell cycle analysis, cells were fixed in 70% ethanol and
resuspended in 33 mg/mL propidium iodide (PI) (Sigma-Aldrich Co.)
supplemented with 1 mg/mL RNase A (Sigma-Aldrich Co.) and 10%
Triton X-100. Samples were incubated for 30 min and analyzed by
flow cytometry using a Cytomics FC500 (Beckman Coulter Inc). For
apoptosis analysis, detached cells were stained with annexin V and PI
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using the ApoScreen TM Annexin V Apoptosis kit (SouthernBiotech).
Cell death was measured as cells staining positive for annexin V, PI,
or both, as assessed by flow cytometry analysis.
Caspase-3/7 activity test
Cells were treated as described for the cell viability assay with 10
mg/mL of antibodies for 24 h. The Caspase-Glo 3/7 Assay (Promega)
was used to measure caspase-3/7 activity. Caspase 3/7 activity was
calculated as follows: Caspase 3/7 activity = (luminescent unit of
treatment well - luminescent unit of blank well)/(mean luminescent
unit of control well - luminescent unit of blank well).
Downstream signaling
Cells were treated as described in section 2.4 for 24 h, washed with
ice-cold PBS, and lysed in a cell lysis solution [50 mM Tris, pH 7.4,
150 mM NaCl, 1% NP-40, 0.1% sodium dodecyl sulfate, 1 mM NaF,
1 mM Na3VO4, 1 mM PMSF, and protease inhibitor cocktail (Sigma)].
Antibodies against HER2 (#4290), pHER2 (#2243), pHER3 (#4791),
EGFR (#4267), pEGFR (#3777), AKT (#4691), pAKT (#4060), ERK
(#4695), and pERK (#4370) were purchased from Cell Signaling
Technology. Anti-HER3 (sc-285) antibody was purchased from
SantaCruz Biotechnology and anti-GAPDH (AbC-1001) antibody was
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purchased from AbClon. Horseradish peroxidase-conjugated
anti-mouse (AbC-5001) and anti-rat (AbC-5003) antibodies were
purchased from AbClon. Bands were visualized using AbSignal
(AbClon, AbC-3001).
Antibody-dependent cellular cytotoxicity (ADCC) assay
SK-BR-3 cells were used as target cells, and human peripheral blood
mononuclear cells (PBMCs) purified from the blood of five healthy
donors were used as effector cells. Target cells (10,000) were
incubated for 15 min with the indicated antibodies followed by the
addition of effector cells at a ratio of 1:50 (target:effector) and
incubation for an additional 20 h at 37°C under 5% CO2. ADCC was
determined using the EZ-LDH Cell Cytotoxicity Assay Kit (DoGen)
according to the manufacturer’s instructions. Cytotoxicity (%) was
calculated using the following equation: (Experimental value –
Effector Cell Spontaneous Control – Target Cell Spontaneous
Control)/(Target Cell Maximum Control – Target Cell Spontaneous
Control) × 100.
Optimization of 1E11 antibody
The humanized 1E11 antibody was developed by CDR-grafting into
human germline genes. The homologous human germline genes with
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highest sequence similarity were selected using IMGT/V-QUEST
(Brochet et al., 2008). The IGKV1-39*01 and IGKJ1*01 genes for
light chain and IGHV3-48*03 and IGHJ4*01 genes for heavy chain
were selected as acceptor sequences for the grafting of murine CDRs.
One residue in heavy chain H47 according to the Kabat numbering
scheme was back-mutated to murine, since this site is responsible for
stabilizing the CDR loop structure as well as modifying its position
(Foote and Winter, 1992).
For affinity maturation of humanized 1E11, CDR3 residues in the
heavy and/or light chain were randomized to 20 amino acids, and
high affinity binders were selected using phage display. Selected
clones were ranked based on the Koff value using SPR analysis with
immobilized HER2-ECD protein. The oz1E11 antibody has four amino
acid mutations in CDR3 of the parental light chain and showed a
>10-fold improvement in Koff value.
NCI-N87 and OE-19 xenograft models
Athymic nude female mice (Daehan Biolink, Korea) were injected
subcutaneously in the left flank area with 5 × 106 of NCI-N87 or
OE-19 cells in Matrigel (BD Biosciences). Tumors were allowed to
grow to approximately 200 mm3 or 500 mm3 in size, and mice were
than randomized into groups. Animals received intraperitoneal
administration of antibodies at the indicated doses twice weekly.
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Tumor volumes were calculated using the formula (L×W×W)/2,
where “L” represents the larger tumor diameter and “W” represents
the smallest tumor diameter. Animals were sacrificed, and the tumors
were isolated and weighted after the termination of studies. Animals
in the study group were also sacrificed if the average tumor volume
was >3,000 mm3. Tumor xenograft tissues were resected and
processed as formalin-fixed, paraffin-embedded specimen sections.
The TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end
labeling) assay was performed to analyze apoptotic cell death. Cells
were visualized under a light microscope.
All animal studies were conducted in accordance with the guidelines
of the NIH “Guide for Care and Use of Animals” and an approved
protocol received by the company’s Institution Animal Care and Use
Committee.
Statistical analysis
Statistical analysis was performed by Student unpaired t test to
identify significant difference unless otherwise indicated. Differences
were considered significant at a P value <0.05.
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Results
1E11 synergistically inhibits gastric cancer cell growth in
combination with trastuzumab
Mouse monoclonal antibodies against the ECD of HER2 were
developed using our improved hybridoma technology. These clones
were used to assess cell viability in a panel of gastric cancer cell
lines including NCI-N87 and breast cancer cell lines including
BT-474. 1E11 was selected based on its affinity for HER2 and
efficacy against HER2-positive cancer cells, and was further
developed into a mouse/human chimeric antibody with the IgG1 kappa
format.
1E11 and trastuzumab showed moderate antiproliferative activity
against HER2-overexpressing gastric NCI-N87 cells as single agents,
whereas in combination they showed dramatically increased
antiproliferative activity (Fig. 5A). Pertuzumab did not show any
substantial antiproliferative activity as a single agent or in
combination with trastuzumab in NCI-N87 cells. The combination
effect of 1E11 and trastuzumab was equivalent to that of trastuzumab
and pertuzumab in HER2-overexpressing BT-474 breast cancer cells
(Fig. 5B).
Combination effects were analyzed using the method of Chou and
Talalay (Chou and Talalay, 1984) to obtain drug combination index
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(C.I.) values. The combination effects of drugs are defined as
synergism, addition, and antagonism according to C.I. values <1.0,
equal to 1.0, or >1.0, respectively. The combination effect of 1E11 and
trastuzumab was determined as strong synergism with C.I. values of
0.03, 0.05, and 0.08 at ED50, ED75, and ED90, respectively.
The in vitro antiproliferative activity of 1E11 in combination with
trastuzumab was confirmed in vivo in mice bearing NCI-N87
xenograft tumors. Both trastuzumab and 1E11 significantly reduced
tumor volume and weight compared to control antibody when used as
single agents (Fig. 6A and 6B); however, when used in combination,
their antitumor activity was significantly higher than that of
trastuzumab alone (P < 0.0001). The tumor growth inhibition (TGI)
value of the antibody combination (95.1%) was much higher than
those of trastuzumab and 1E11 as single agents (48.6% and 39.9%,
respectively).
These results indicate that 1E11 in combination with trastuzumab
inhibits HER2-overexpressing gastric cancer cell growth in a
synergistic manner.
1E11 binds to domain IV of HER2 at a distinct epitope different
from that of trastuzumab
To determine whether 1E11 binds to the same epitope as trastuzumab
or pertuzumab, the binding of 1E11 to the HER2-ECD that was
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Figure 5. 1E11 shows antiproliferative activity in combination
with trastuzumab in a synergistic manner
A, NCI-N87 and B, BT-474 cells were treated with hIgG,
trastuzumab (TRA), pertuzumab (PER), and 1E11 as single agents
and in combination with trastuzumab in a 1:1 ratio for 4 days. Cell
viability was expressed as the mean ± SD (n = 3), and the 100%
point was defined as the absorbance of the untreated well.
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Figure 6. 1E11 shows antitumor activity in combination with
trastuzumab in xenograft model
A, NCI-N87 cells were inoculated into mice (n = 5 mice/group each)
and treatment with 10 mg/kg of antibody was started when tumor
volumes reached approximately 200 mm3. For combination treatment,
10 mg/kg of each antibody was administered. Palivizumab was used
as the isotype control antibody. Administration days are indicated by
arrows. Tumor volume (mm3) was expressed as mean ± SD. B,
Tumor masses were isolated after measuring tumor weight.
Statistically significant differences were determined by Student’s t




occupied by trastuzumab or pertuzumab was analyzed by SPR. As
shown in Figure 7A, 1E11 was able to bind a monomeric
HER2-ECD-His protein captured by immobilized pertuzumab (Fig.
7A). These data indicate that 1E11 binds to a distinct epitope that is
different from the epitopes of trastuzumab or pertuzumab, and that it
is capable of simultaneous binding to HER2 with the two other
antibodies.
Recombinant HER2-ECD domain fragments were used for epitope
mapping of the three reagents (Fig. 7B), which showed that both
1E11 and trastuzumab bound to sub-domain IV. However, pertuzumab
did not bind to domain II of recombinant HER2, suggesting that it
was not able to mimic its natural conformation. To further
characterize the 1E11 epitope, the binding of 1E11 to 15-mer peptides
with a peptide-peptide overlap of 14 amino acids covering the whole
HER2-ECD was examined. However, no significant binding signals
were detected for any of the peptides (data not shown). Taken
together, these results indicated that 1E11 binds to a discontinuous or
conformational epitope in sub-domain IV.
Recombinant ErbB proteins were used to confirm that 1E11, similar
to trastuzumab and pertuzumab, specifically binds HER2 and not the
other human ErbB family members (Fig. 8A). The species
cross-reactivity of 1E11 was determined by assessing the binding
activity of 1E11 to HER2-ECD proteins from five different species.
Similar to trastuzumab and pertuzumab, 1E11 bound to monkey HER2
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Figure 7. 1E11 binds to a sub-domain IV epitope different from
that of trastuzumab
A, Pertuzumab was immobilized on a CM5 sensor chip followed by
sequential exposure to HER2-ECD-His, trastuzumab, and 1E11. B,




Figure 8. 1E11 specifically binds to HER2 in ErbB family and
has species cross-reactivity with rhesus and cynomolgus
monkey HER2 proteins
A, The ErbB family cross-reactivity of 1E11 was analyzed using
recombinant human ErbB proteins. Cetuximab (CET) was used as the
control antibody for the EGFR protein. B, The species
cross-reactivity of 1E11 was analyzed using recombinant HER2 ECD
proteins of the indicated species.
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but not murine HER2 proteins (Fig. 8B).
1E11 increases tumor cell apoptosis in combination with
trastuzumab
To determine the mechanism underlying the antitumor activity of
1E11, cell cycle progression and apoptosis were analyzed by flow
cytometry. Treatment of NCI-N87 cells with trastuzumab or 1E11 did
not induce significant changes in the cell cycle either as single agents
or in combination (Fig. 9A). However, combination treatment with
1E11 and trastuzumab increased the sub-G1 population of NCI-N87
cells, indicating cell death.
Assessment of cell apoptosis showed that 1E11 increased both the
early and late apoptotic cell population compared to trastuzumab or
pertuzumab single agent treatments, and this apoptotic activity was
further increased in NCI-N87 cells exposed to combination treatment
with 1E11 and trastuzumab (Fig. 9B). Trastuzumab alone did not
induce apoptosis in NCI-N87 cells even after a two-fold increase in
dose (data not shown). The effect of 1E11 was confirmed in the
BT-474 cell line, where it showed a similar effect as a single agent
and in combination with trastuzumab (Fig. 9C). To confirm that the
cytotoxic effect of 1E11 is mediated by the induction of apoptosis, the
activity of caspase-3 and -7 was examined in NCI-N87 cells.
Caspase-3/7 activity increased slightly after 24 h of treatment with
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Figure 9. 1E11 induces apoptosis in combination with
trastuzumab
A, NCI-N87 cells were treated with antibodies for 48 h, stained with
propidium iodide (PI), and DNA content was measured by flow
cytometry. The relative cell populations in sub-G1 (subdiploid), G1, S,
and G2-M phases are shown. B, NCI-N87 and C, BT-474 cells were
treated with antibodies for 48 h and stained with annexin
V-phycoerythrin (PE) and PI. Cell death was assessed by flow
cytometry. The percentage of cells staining positive for annexin V
(early apoptosis) and annexin V and PI (late apoptosis) are shown. D,




trastuzumab as a single agent, whereas a 1.6-fold increase was
observed in response to combination treatment with 1E11 (Fig. 9D).
These results indicate that 1E11 exhibits antiproliferative activity by
inducing apoptotic cell death, and its apoptotic activity is further
increased in combination with trastuzumab in NCI-N87 gastric cancer
cells.
1E11 inhibits ErbB family signaling and ligand-induced cell
proliferation in combination with trastuzumab
To elucidate the mechanism underlying the antiproliferative activity of
1E11 in combination with trastuzumab, the levels of the HER2 protein
and related signaling molecules were measured. Combination
treatment with 1E11 and trastuzumab or with pertuzumab and
trastuzumab reduced total HER2 and phosphorylated HER2 levels
(Fig. 10A). Combination treatment decreased the levels of activated
HER3 and EGFR without affecting total protein levels and
significantly downregulated the activated form of the HER2
downstream factors AKT and ERK while the total protein levels
remained unchanged. These results suggest that 1E11 in combination
with trastuzumab inhibits the activity of ErbB family proteins and
suppresses downstream signaling.
To evaluate the significance of ErbB family receptor signaling in the
response of HER2-overexpressing gastric cancer cells to antibody
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Figure 10. 1E11 inhibits HER2 downstream signaling and
heterodimerization-induced cell proliferation
A, NCI-N87 cells were treated with 10 mg/mL of antibodies for 24 h
under normal growth conditions, and changes in HER2 and HER3
downstream signaling were monitored by western blotting.
Phosphorylated proteins were detected using antibodies against
well-characterized activation site residues. B, Cell growth inhibition in
the presence of HRG1 or EGF was examined. Cell proliferation was
assessed 3 days after the indicated treatments. Data points represent
the mean ± SD (n = 3).
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treatment, the antiproliferative activity of antibodies was analyzed
under ligand-induced dimerization conditions. The induction of cell
proliferation by HRG1 and EGF in NCI-N87 cells (Fig. 10B) was not
inhibited by trastuzumab or 1E11 as a single agent, whereas
pertuzumab inhibited ligand-induced cell proliferation as previously
reported (Nahta et al., 2004). Combination treatment with 1E11 and
trastuzumab inhibited ligand-induced proliferation to a similar level as
the combination of trastuzumab and pertuzumab, suggesting that 1E11
in combination with trastuzumab could compensate for the effect of
pertuzumab. These results suggested that in addition to the inhibition
of ErbB family dimerization, other mechanisms are involved in the
effect of combination treatment with 1E11 and trastuzumab on the
inhibition of cell proliferation in HER2-overexpressing gastric cancer
cells.
The antiproliferative activity of optimized 1E11 antibody
(oz1E11) is dependent on HER2 expression
The oz1E11 antibody was developed by humanization and affinity
maturation of 1E11. The binding affinity of oz1E11 for the ECD of
HER2 (monomer) was 1.9 nM as determined by SPR, whereas that of
the parental 1E11 antibody was 23 nM. The ADCC activity of oz1E11
was comparable to that of trastuzumab or pertuzumab in the lactate
dehydrogenase (LDH) release assay performed using SK-BR-3 cells
and PBMCs (Fig. 11) (Arnould et al.,
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Figure 11. oz1E1 mediates antibody-dependent cellular
cytotoxicity of SK-BR-3
The antibody-dependent cellular cytotoxicity of antibodies was
measured using an assay that detects LDH released from lysed cells.
Peripheral blood mononuclear cells were used as effector cells and
HER2 overexpressing SK-BR-3 cells were used as target cells with
1:50 target:effector ratio. Cytotoxicity was expressed as the mean ±




The antiproliferative activity of oz1E11 was examined in seven
gastric cancer and two breast cancer cell lines. The oz1E11 antibody
showed moderate antiproliferative activity as a single agent in
HER2-overexpressing gastric cancer and breast cancer cells (Fig. 12),
whereas in combination with trastuzumab, its antiproliferative activity
was superior to that of pertuzumab or trastuzumab alone or in
combination in HER2-overexpressing NCI-N87 and OE-19 gastric
cancer cell lines (Fig. 13). Changes in cell viability in response to
oz1E11 were correlated with HER2 levels in treated cells (Fig. 14),
suggesting that the antiproliferative activity of oz1E11, both as a
single agent and in combination with trastuzumab, is dependent on
HER2 expression. The oz1E11 antibody showed high efficacy against
HCC-202 breast cancer cells, which are HER2-positive but
trastuzumab-resistant, whereas it showed little activity against other
trastuzumab-resistant cell lines including HCC-1954 (Fig. 15).
The antiproliferative activity of oz1E11 was confirmed in vivo in
NCI-N87 and OE-19 xenograft models. Tumors were treated when
reaching a volume of 200 mm3 or 500 mm3 to evaluate the effect of
the antibody on TGI and regression. Combination treatment with
oz1E11 and trastuzumab showed superior antitumor activity to that of
each agent alone in both xenograft models. In the in vivo efficacy
study using NCI-N87 cells, pertuzumab showed increased antitumor
activity when used in combination with trastuzumab, which was
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different from the results of the in vitro study. Both oz1E11 and
pertuzumab caused complete regression of NCI-N87 xenograft tumors
when used in combination with trastuzumab (Fig. 16) However, in
the OE-19 xenograft model, only the combination of oz1E11 and
trastuzumab completely inhibited tumor growth, and pertuzumab and
trastuzumab in combination caused partial inhibition of tumor growth
(Fig. 17). Isolated OE-19 and NCI-N87 xenograft tumors were
subjected to the TUNEL assay, which showed a higher number of
apoptotic cells in tissues treated with oz1E11 that was further
increased in response to combination treatment with oz1E11 and
trastuzumab (Fig. 18).
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Figure 12. oz1E11 shows antiproliferative activity in
HER2-overexpressing gastric and breast cancer cells
Human gastric and breast cancer cells were treated with 5 mg/mL of
antibodies for 3 or 4 days and cell viability was determined (upper
panel). The expressions of HER2, EGFR, and HER3 in 20 mg of total
cell lysate were determined by western blotting (bottom panel). Cell
viability was expressed as the mean ± SD (n = 3), and the 100%
point was defined as the absorbance of the untreated well.
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Figure 13. oz1E11 shows synergistic antiproliferative activity in
combination with trastuzumab in HER2-overexpressing gastric
cancer
Dose-effect curves of antibodies in NCI-N87 (A) and OE-19 (B) cells
are shown. Cell viability was expressed as the mean ± SD (n = 3),




Figure 14. Expression of HER2 and EGFR in gastric and breast
cancers
HER2 (A) and EGFR (B) expression levels were determined by flow
cytometric analysis of 100,000 cells stained with 1 mg of trastuzumab
or cetuximab for the detection of HER2 and EGFR, respectively.
Control levels were determined with secondary antibody. Data points
are the mean ± SD (n = 2) of the mean fluorescence intensity (MFI).
58
59
Figure 15. oz1E11 shows antiproliferative activity in
trastuzumab-resistant breast cancer cells
A, Human breast cancer cells were treated with 5 mg/mL of
antibodies for 3 or 4 days and cell viability was determined. B, A
dose-effect curve of antibodies in HCC-202 cells is shown. Cell
viability was expressed as the mean ± SD (n = 3), and the 100%
point was defined as the absorbance of the untreated well.
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Figure 16. oz1E11 causes tumor regression in NCI-N87 gastric
tumor xenograft models in combination with trastuzumab
A, NCI-N87 cells were inoculated into mice (n = 6 mice/group each),
and treatment with 10 mg/kg of antibody was started when tumor
volumes reached approximately 200 mm3. For combination treatment,
10 mg/kg of each antibody was administered. B, NCI-N87 (n = 5
mice/group) cells were inoculated into mice and antibody treatments
were started when tumor volumes reached approximately 500 mm3.
Mice received a dose of 20 mg/kg for single agent treatment and 10
mg/kg of each antibody for combination treatment. Administration
days are indicated by arrows. Tumor volume (mm3) was expressed
as the mean ± SD. Statistically significant differences were




Figure 17. oz1E11 causes tumor regression in OE-19 gastric
tumor xenograft models in combination with trastuzumab
A, OE-19 cells were inoculated into mice (n = 6 mice/group each),
and treatment with 10 mg/kg of antibody was started when tumor
volumes reached approximately 200 mm3. For combination treatment,
10 mg/kg of each antibody was administered. B, OE-19 (n = 3
mice/group) cells were inoculated into mice and antibody treatments
were started when tumor volumes reached approximately 500 mm3.
Mice received a dose of 20 mg/kg for single agent treatment and 10
mg/kg of each antibody for combination treatment. Administration
days are indicated by arrows. Tumor volume (mm3) was expressed
as the mean ± SD. Statistically significant differences were




Figure 18. Apoptotic activity of oz1E11 in xenograft models
A, Tumor masses were isolated after the OE-19 xenograft study
described in Figure 17B that antibody treatments were started when
tumor volumes reached approximately 500 mm3. TUNEL assay was
followed using these OE-19 cell mass (B). C, Another TUNEL assay
was conducted with isolated tumor masses from NCI-N87 xenograft
study that antibody treatments were started when tumor volumes
reached approximated 500mm3 (Fig. 16B). *oz1E11-A is another




HER2 targeted therapy has shown promising results in the treatment
of gastric cancer, and trastuzumab has been approved for the
treatment of patients with HER2-overexpressing gastric cancer.
However, despite encouraging clinical results obtained with
trastuzumab, the development of more potent targeted therapies for
HER2-positive gastric cancer is necessary to increase overall survival
rates (Bang et al., 2010). Combination of non-competing antibodies
targeting receptor proteins can increase antitumor activity in vitro
and in vivo (Kamat et al., 2008; Pedersen et al., 2010; Tvorogov et al,
2010; and Zhang et al., 2010). Pertuzumab is the first approved
antibody to be used in combination for dual targeting of the same
protein in the treatment of metastatic breast cancer (Baselga et al.,
2012). In the present study, efforts to identify a superior therapeutic
antibody for HER2-overexpressing gastric cancer resulted in the
development of 1E11. 1E11 inhibits HER2-overexpressing gastric
cancer cell growth in in vitro and in vivo models in combination with
trastuzumab, enhancing its apoptotic activity in a synergistic manner.
Unlike pertuzumab and trastuzumab, 1E11 and trastuzumab bind to
the same sub-domain (IV) of HER2. To the best of our knowledge,
this is the first antibody combination targeting the same sub-domain
of the HER2 protein with potential therapeutic application in the
treatment of gastric cancer.
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HER2/HER3 heterodimerization is one of the most common
mechanisms triggering aberrant HER2 signaling in breast cancer
(Baselga and Swain, 2009 and Olayioye et al., 2000), and pertuzumab
has shown antitumor activity through the inhibition of HER2/HER3
dimerization in non-small cell lung cancer and breast cancer
(Lee-Hoeflich et al., 2008 and Sakai et al., 2007). The NCI-N87 cell
line has previously been used as a model system for research on
HER2-overexpressing gastric cancer (Kim et al., 2008; Patel et al.,
2009; Tanner et al., 2005; and Yamashita-Kashima et al., 2011). In the
present study, NCI-N87 cell proliferation was increased by the HER2
heterodimerizing ligands HRG1 and EGF, and treatment with
pertuzumab efficiently inhibited ligand-induced cell proliferation as
demonstrated previously (Fig. 10B). 1E11 in combination with
trastuzumab inhibited ligand-induced cell proliferation to a similar
level as the pertuzumab/trastuzumab combination, suggesting that the
effect of 1E11 in combination with trastuzumab is mediated by the
inhibition of HER2 heterodimerization. Pertuzumab did not show
significant antiproliferative activity as a single agent or in
combination with trastuzumab in NCI-N87 and OE-19 cells. By
contrast, the antiproliferative activity of 1E11 increased when used in
combination with trastuzumab. These results suggest that blocking
HER2 heterodimerization with EGFR or HER3 is not fully sufficient
to induce cell death in HER2-overexpressing gastric cancer.
One of the hallmarks of cancer is resistance to apoptosis (Hanahan
and Weinberg, 2011 and Susnow et al., 2009), and the induction of
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apoptosis is an important antitumor mechanism of therapeutic
antibodies (Ben-Kasus et al., 2007). The CD20-targeting antibody
rituximab activates caspase-3 through a mechanism involving Src
family kinases, and the EGFR-targeting antibody cetuximab
upregulates the pro-apoptotic protein Bax and downregulates the
anti-apoptotic protein Bcl-2 (Hofmeister et al., 2000 and Huang et al.,
1999). HER2 suppresses pro-apoptotic Bad and Bim through AKT
(Datta et al., 1997 and Tanizaki et al., 2011), and AKT regulates
several members of the forkhead family of transcription factors
related to apoptosis (Chakrabarty et al., 2013 and Real et al., 2005).
Recently, translocation of HER2 to mitochondria was shown to
contribute to trastuzumab resistance by decreasing the activity of
cytochrome c oxidase in a HER2-dependent manner (Ding et al.,
2012). 1E11 significantly induced apoptosis in NCI-N87 cells as single
agent and in combination with trastuzumab (Fig. 9B and 9C), and the
apoptotic activity of 1E11 was confirmed in xenograft model (Fig. 18).
As reported earlier (Nahta et al., 2004) and confirmed here, the
apoptotic activity of trastuzumab is limited. Therefore, the synergistic
increase in antitumor activity by the combination of 1E11 and
trastuzumab could be attributed to the apoptotic activity of 1E11. The
apoptotic cancer cell death induced by 1E11 and trastuzumab in
combination could be mediated by the downregulation of HER2 and
inhibition of PI3K-AKT signaling. 1E11 and trastuzumab combination
treatment increased effector caspase-3/7 activity confirming that the
apoptotic activity of 1E11 (Fig. 9D). Trastuzumab alone induces cell
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cycle arrest in BT-474 cells as previously reported (Brockhoff et al.,
2007). However, in the present study, trastuzumab and 1E11 did not
cause significant cell cycle arrest as single agents or in combination
in NCI-N87 cells.
Despite the important roles of sub-domains II and IV of the HER2
extracellular region in ErbB family dimerization activation of
downstream signaling pathways associated with cell growth (Burgess
et al., 2003), the exact role of sub-domain IV remains unknown. It
has been reported that trastuzumab disrupts HER2/HER3
heterodimer-formation under ligand-independent conditions (Junttila et
al., 2009); however, the direct interaction of HER2 with non-ErbB
family members such as CD44, MUC4, and IGF-1R plays a role in
tumor development and trastuzumab resistance (Balana et al., 2001;
Bourguignon et al., 1997; and Nagy et al., 2005). Pertuzumab inhibits
HER2 and IGF-1R dimerization in trastuzumab-resistant breast cancer
cells, although it does not significantly inhibit cell growth (Nahta et
al., 2005). 1E11, in combination with trastuzumab, inhibited
ligand-induced cell proliferation to a similar level as pertuzumab,
despite the fact that 1E11 binds to a non-overlapping epitope in
sub-domain IV that is not associated with the dimerization arm (Fig.
7). Similar to previously reported antibody combinations, the 1E11 and
trastuzumab combination could inhibit HER2 dimerization with other
non-ErbB2 family members, resulting in cancer cell apoptosis and/or
downregulation of HER2 (Ben-Kasus et al., 2009; Kamat et al., 2008;
and Pedersen et al., 2010). oz1E11 had antiproliferative effects against
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HCC-202, a HER2-positive but trastuzumab-resistant breast cancer
cell line, although the mechanism by which oz1E11 overcomes
trastuzumab resistance in this particular cell line remains unclear.
Further investigation is necessary to improve our understanding of
the mode of action of oz1E11 (Fig. 15).
In conclusion, 1E11 showed synergistic antitumor activity in
combination with trastuzumab in HER2-positive human gastric cancer
in vitro and in vivo. The antitumor activity of 1E11 was mediated by
its apoptotic activity and the inhibition of HER2 homo-and
hetero-dimerization downstream signaling. To the best of our
knowledge, 1E11 and trastuzumab is the first antibody combination
targeting the same sub-domain of HER2. This antibody combination
could be a useful tool to improve our understanding of the
biochemical properties of HER2 and a novel potent therapeutic
strategy for the treatment of patients with HER2-overexpressing
gastric and breast cancer.
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CHAPTER II
Optimization of a HER2 targeting mouse
monoclonal antibody 1E11 for therapeutic
development using human germline genes and
targeted randomization of CDR-L3
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Abstract
The mouse monoclonal antibody 1E11, targeting epidermal growth
factor receptor 2 (HER2), shows synergistic antitumor activity in
HER2-overexpressing gastric cancer cells when used in combination
with trastuzumab. In the present study, I optimized this antibody for
therapeutic development. First, the CDRs of the mouse antibody were
grafted onto human germline immunoglobulin variable genes. No
difference in affinity and biological activity was observed between
chimeric 1E11 (ch1E11) and humanized 1E11 (hz1E11). Next, affinity
maturation of hz1E11 was performed by the randomization of CDR-L3
and H3 residues followed by stringent biopanning selection. It was
observed that milder selection pressure favored the selection of more
diverse clones, whereas higher selection stringency resulted in the
convergence of the panning output to a smaller number of clones
with improved affinity. The clone 1A12 had 4 amino acid
substitutions in CDR-L3, and showed a 10-fold increase in affinity
compared to the parental clone and increased potency in the
antiproliferative activity assay with HER2-overexpressing gastric
cancer cells. The clone 1A12 inhibited the tumor growth of NCI-N87
and OE-19 xenograft models with similar efficacy to trastuzumab as
a single agent, and the combination treatment of 1A12 and
trastuzumab completely removed the established tumors. These results
suggest that humanized and affinity matured monoclonal antibody
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1A12 is a highly optimized molecule for future therapeutic




Monoclonal antibodies are mainstream treatments in oncology and
autoimmune diseases and expected to play an important roles in the
future of diseases treatment (Chan and Carter, 2010; Weiner et al.,
2010). More than thirty recombinant antibodies are currently approved
by the US FDA, of which the approximately a half are anti-cancer
antibodies. Gastric cancer is one of the most common cancers, and is
the third leading cause of cancer death worldwide (Ferlay et al.,
2012). In gastric cancer, overexpression of EGFR, HER2, and HER3 is
correlated with poor prognosis (Garcia et al., 2003 and Hayashi et al.,
2008). Recently, the HER2 targeting monoclonal antibody trastuzumab
was approved for the treatment of HER2-positive metastatic gastric
and gastroesophageal junction cancer based on ToGA clinical trial
(Bang et al., 2010).
Particular combinations of noncompetitive antibodies targeting the
same receptor increase antitumor activity in vitro and in vivo.
Combination of HER2 targeting antibodies, trastuzumab and
pertuzumab, shows increased efficacy in HER2-overexpressing breast
cancers (Nahta et al., 2004). The benefits of the pertuzumab and
trastuzumab combination were further demonstrated in preclinical and
clinical trials (Baselga et al., 2010 and Scheuer et al., 2009). Other
HER2-targeting antibodies showing better efficacy in combination
than as single agents have been reported, and have shown consistent
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downregulation of HER2 levels and beneficial combination effects in
mouse models (Ben-Kasus et al., 2009). The increased efficacy of
antibody combinations has also been demonstrated with
EGFR-targeting antibodies (Kamat et al., 2008; Pedersen et al., 2010)
and VEGFR3-targeting antibodies (Tvorogov et al, 2010).
Therapeutic antibodies typically are extensively engineered, so that
they possess desirable biological and physicochemical properties such
as low immunogenicity, high affinity and specificity, optimal effector
functions, and good solubility and stability (Igawa et al., 2012).
Especially, antibody humanization and affinity maturation are two of
the most frequently applied engineering processes during the
development of therapeutic antibody candidates. Immunogenicity of
therapeutic antibody limits the clinical utility and efficacy by
production of anti-drug antibodies (Hwang and Foote, 2005), and the
humanization of the antibodies from mouse or other species is now a
standard procedure for the development of therapeutic antibodies.
Many humanization methods have been developed that employ either
rational or empirical approaches (Almagro and Fransson, 2008). The
complementarity-determining region (CDR) grafting approach as a
method to overcome the human anti-chimeric antibody (HACA)
response (Jones et al., 1986) is a well-established humanization
method. However, direct grafting of murine CDRs onto a human
framework acceptor sequence often results in a loss of affinity, so
back-mutations of framework region residues (Vernier zone residues;
see (Almagro and Fransson, 2008)) supporting the structure of CDR
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loops is often necessary (Foote and Winter, 1992). For in vitro
affinity maturation, three diversification approaches are typically used:
random mutagenesis by e.g. error-prone PCR, randomization of
targeted residues, and chain shuffling. In the targeted randomization
approach, CDRs are the target for the randomization in most cases
because somatic hypermutation has evolved to favor mutations in
CDRs of antibodies (Wu et al., 2003) and CDR-H3 and CDR-L3 tend
to dominate the antibody-antigen interaction (Sundberg and Mariuzza,
2002). One of the main problems associated with the targeted
randomization is selecting the positions that are not essential for the
antigen binding, but can enhance the affinity when optimal
substitution of amino acid is made. Alanine scanning can help
deciding which residues to randomize, especially when CDRs are long.
Sometimes, alanine mutation itself increases the affinity of antibodies
(Kawa et al., 2011).
Previously we developed a mouse antibody targeting HER2 (clone
1E11) that shows synergistic antitumor activity in combination with
trastuzumab in HER2 overexpressing gastric cancer cell lines (in
press). In this study, we report the optimization of 1E11 for
therapeutic development, by CDR grafting to human germline
immunoglobulin variable genes and affinity maturation through
targeted randomization of CDR-H3 and CDR-L3. The optimized 1E11
antibody (clone 1A12) shows synergistic antitumor activity in
HER2-positive gastric cancer xenograft models in combination with
trastuzumab. It was observed that for the clone 1E11, human
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germline variable genes are suitable acceptors for humanization
without affinity reduction, and randomization of non-essential residues
in CDR-L3 is enough to improve the affinity by more than 10-fold.
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Materials and Methods
Cell lines and materials
NCI-N87 cells were purchased from American Type Culture
Collection (ATCC) and OE-19 cells were obtained from the European
Collection of Cell Culture (ECACC). Cell culture media were
RPMI-1640 supplemented with 10% fetal bovine serum (FBS), and
antibiotics and cells were cultured at 37°C under 5% CO2.
Trastuzumab were produced by Genentech Incorporated (South San
Francisco, CA, USA), and palivizumab was produced by MedImmune,
LLC (Gaithersburg, MD, USA). ChromPure human IgG (Jackson
Immunoresearch Lab, West Grove, PA, USA) was used as human
IgG control antibody in in vitro assays. IgG antibodies were produced
using the Freestyle 293 system (Invitrogen) and purified using
protein-A chromatography (GE Healthcare). Endotoxin was removed
with an Endotoxin removal kit (GenScript), and endotoxin levels were
determined using an Endotoxin detection kit (GenScript). Recombinant
proteins were produced as secretion proteins using the 293F system
and purified using protein-A or Ni-NTA chromatography (Qiagen
Inc.) for Fc-tagged and His-tagged proteins, respectively.
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Alanine-scanning mutagenesis and Fab purification
Site-directed mutagenesis for alanine scanning was accomplished by
PCR mutagenesis using QuickChange Site-Directed Mutagenesis Kit
(Agilent Technologies). Mutant Fab proteins were expressed and
purified to evaluate the importance of each residue for antigen
binding activity. In brief, E.coli DH5α cells, transformed with the
pComb3X vector harboring mutant Fab genes, were grown at 28℃ in
SB broth; expression was induced with 1 mM IPTG when the optical
density (600 nm) of the culture reached 0.8. Cell pellets were
resuspended in chilled extraction buffer (120 mM Tris pH 8.0, 0.3
mM EDTA, and 300 mM sucrose) and incubated on ice for 30 min
for periplasmic extraction. Magnesium chloride (2.5 mM) was added
to the clarified extract prior to immobilized metal ion affinity
chromatography (IMAC) purification. Purified Fab proteins were used
for ELISA binding assay and koff analysis using surface plasmon
resonance (SPR).
Affinity maturation
Humanized 1E11, cloned in pComb3X vector as Fab format, was
utilized as template for overlap extension polymerase chain reaction






TGGGGCCAGGG-3; (forward) were used for L-NNK and H-XXS
library, respectively. N denotes A, C, G or T; K is G or T; and S is
G or C. Numbered base positions indicate hand-mixed nucleotides
which are composed of 70% of one base and 10% each of the other
three bases; 70% frequency base is G, A, T, and C for 1, 2, 3, and 4,
respectively. For H-2AA library, equimolar mixture of following
forward mutagenic oligonucleotide were used:
5’-GTCTACTATTGTGCTAGANNKNNKGGTGGGACCGCCTCCTTC
G A C - 3 ’ ,
5’-GTCTACTATTGTGCTAGACACNNKNNKGGGACCGCCTCCTTCG
A C T A C - 3 ’ ,
5’-GTCTACTATTGTGCTAGACACCTGNNKNNKACCGCCTCCTTCG
A C T A C T G G - 3 ’ ,
5’-GTCTACTATTGTGCTAGACACCTGGGTNNKNNKGCCTCCTTC




GACTAC TGGGGCCAGGG-3’. After two round of overlap extension
PCR, Fab library DNA with a randomized CDR was cut with SfiI,
ligated into SfiI- digested phagemid vector pComb3X, and
electrotransformed into Escherichia coli strain ER2537 (New England
Biolabs, Beverly, MA).
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High affinity binders were selected using soluble biotinylated
HER2-ECD protein. Bead binders were pre-depleted by incubating the
antibody phage library with 100 mL of pre-blocked Dynabeads M-280
Streptavidin (Invitrogen) for 1 h with gentle rotation at room
temperature. Biotinylated HER2-ECD protein (100 nM – 0.1 pM) was
added to the pre-depleted antibody library and incubated for 1 h with
rotation at room temperature. Then 50 mL of blocked
streptavidin-magnetic beads were added and incubated on the rotator
for 15 min. Beads were washed 10 times with 1 mL of PBS-T buffer
and twice with 1 mL of PBS-T. Remaining phages were eluted by
incubating the beads with 1 mL of 100 mM triethylamine for 8 min
then neutralized with 0.5 mL of 1M Tris, pH 7.4.
ELISA binding activity test
Antibodies were added to Costar 96-well half area plates (Corning)
coated with 25 mg/mL of the antigen. After incubation at RT for 1
h, the plates were washed 3 times with TBST (50 mM Tris, pH7.6,
150 mM NaCl, 0.05% Tween 20) and incubated with goat anti-human
antibody-HRP (Pierce) for IgG antibodies and rat anti-HA-Peroxidase
(Roche) for Fab antibodies, respectively. Plates were washed 3 times,
3,3‘,5,5’-tetramethylbenzidine (TMB) peroxidase substrate (SurModics,
Eden Prairie, USA) was added, and reactions were stopped by adding
1N sulfuric acid (DukSan, Seoul, Republic of Korea). Absorbance at
450-nm was measured using Victor X3 instrument.
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Surface plasmon resonance (SPR) analysis
For koff analysis of Fab proteins, HER2-ECD-His protein was
immobilized onto CM5 sensor chip surface (GE Healthcare) using the
amine coupling method at approximately 2,000 response units (RU).
Purified Fab proteins were injected at 2 mg/mL concentration at 50
mL/min flow rate. For koff analysis of IgG antibodies, goat
anti-human IgG (γ) (Invitrogen) was immobilized onto a CM5 sensor
chip using amine coupling, and antibodies were captured at 1 mg/mL
for 4 min and stabilized for 5 min. Then, HER2-ECD-His protein
was injected at 160 nM concentration. For affinity measurements,
antibodies were captured at approximately 50 RU through goat
anti-human IgG (γ). Then, HER2-ECD-His protein was injected at
concentrations ranging from 0 to 640 nM. Sensorgrams were obtained
at each concentration and evaluated using the BIAevaluation software.
For epitope binning, IgG form of hz1E11 was immobilized onto
separate CM5 sensor chip surfaces at approximately 1000 response
units. HER2-ECD-His (320 nM) and antibodies (1 mg/mL) were
sequentially added by binding for 4 min and stabilization for 5 min at
50 mL/min flow rate.
Cell viability assay
Cells were seeded in 96-well plates (Corning) in growth media
containing 10% FBS and pre-cultured for 24 h. The cells were
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treated with antibodies at the indicated concentrations and culture for
4 days. The WST reagent (DoGen, Daejeon, Republic of Korea) was
used to measure cell viability. Relative cell viability was calculated by
dividing the absorbance of each well by the mean absorbance of
PBS-treated wells in each plate.
Xenograft study
Athymic nude female mice (Daehan Biolink, Korea) were injected
subcutaneously in the left flank area with 5 × 106 of NCI-N87 or
OE-19 cells in Matrigel (BDBiosciences). Tumors were allowed to
grow to approximately 200 mm3 in size, and mice were than
randomized into groups. Animals received intraperitoneal
administration of antibodies at the indicated doses twice weekly.
Tumor volumes were calculated using the formula (L×W×W)/2,
where “L” represents the larger tumor diameter and “W” represents
the smallest tumor diameter.
All animal studies were conducted in accordance with the guidelines
of the NIH’s “Guide for Care and Use of Animals” and an approved




Humanization of 1E11 is conducted by CDR-grafting to human
germline genes
To develop the humanized antibody, the VH and VL sequences of the
murine 1E11 were compared with human germline V and J gene
repertories using IMGT/V-QUEST analysis tools (Brochet et al.,
2008). For the heavy chain, IGHV3-48*03 and IGHJ4*01 exhibited
highest homology to the 1E11 counterparts, sharing 85% and 87%
identity, respectively. For the light chain, human IGKV1-39*01 and
IGKJ1*01 genes displayed identity of 80% and 81%, respectively.
These human genes were selected as acceptor sequences for the
grafting of the murine CDRs. Among “Vernier zone” which consists
of residues in the framework region that are involved in the
presentation of CDR structures by supporting the CDR loops (Foote
and Winter, 1992 and Makabe et al., 2008), only one residue at
position 49H of heavy chain differed between murine and human
sequences. Consequently, humanized 1E11, hz1E11, has only one
murine residue in framework region (Fig. 19).
Binding activity of hz1E11 to extracellular region (ECD) of HER2
was equivalent to that of ch1E11 (Fig. 20A), and the affinities of
trastuzumab, ch1E11 and hz1E11 were 3 nM, 23 nM, and 23 nM,
respectively. We also confirmed that hz1E11 bound to sub-domain IV
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Figure 19. Humanization of 1E11 by CDR grafting
Heavy chain (A) and light chain (B) amino acid sequence alignment
of murine, human germline, and humanized 1E11. The CDRs, defined
according to Kabat’s nomenclature, are in bold (Kabat et al., 1991).
Amino acids are numbered according to the Kabat numbering scheme.




Figure 20. Humanized 1E11 shows equivalent binding properties
to parental antibody.
A, The binding activities of hz1E11 and ch1E11 to HER2-ECD
protein were analyzed by ELISA. Trastuzumab (TRA) was used as
the control antibody for the HER2 protein. B, The binding activity of




Figure 21. Humanized 1E11 shows synergistic antitumor activity
in combination with trastuzumab.
A, NCI-N87 cells were treated with antibodies for 4 days in the
complete growth media. Data points of cell viability assay are mean
± SD (n = 3) and the 100% point was defined as the absorbance of
antibody untreated well. B, Mice bearing NCI-N87 xenograft tumors
were treated with indicated dose of control antibody, trastuzumab,
hz1E11, or trastuzumab + hz1E11. Palivizumab was used as the
isotype control antibody. Administration days are indicated by arrows.




like the parental ch1E11 (Fig. 20B). Trastuzumab is also known to
bind to sub-domain IV (Cho et al., 2003). The in vitro
antiproliferative activities of hz1E11 as single agent and in
combination with trastuzumab are also equivalent to those of ch1E11
(Fig. 21A). The combination of hz1E11 with trastuzumab showed
dose-dependent antitumor activity in NCI-N87 xenograft mouse model
(Fig. 21B). The result also shows that antibody combination
treatment at 1 mg/kg each of hz1E11 and trastuzumab resulted in
similar antitumor activity with trastuzumab single treatment at 10
mg/kg, and established tumors were started to regress from at 5
mg/kg combination. These results show that hz1E11 has equivalent
affinity and biological activity to ch1E11, and hz1E11 enhance the
antitumor activity of trastuzumab when used in combination.
Alanine scanning of CDR-H3 and CDR-L3
To identify the critical residues for antigen-antibody interaction, we
conducted alanine scanning mutagenesis in CDR3 regions of heavy
and light chain (CDR-H3 and CDR-L3). The effects of the mutations
were assessed by analyzing binding activity of purified Fab proteins
by indirect ELISA. In CDR-H3, alanine substitution at position Gly98H
abolished the binding of the Fab to HER2, and G97HA and T99HA
mutants showed reduced binding activity (Fig. 22A). In CDR-L3,
alanine substitution at position Ser93L resulted in reduced binding and
Y92LA mutants showed enhanced binding activity (Fig. 22B). The koff
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Figure 22. Three residues in heavy chain CDR3 are hot-spot for
antigen-antibody binding.
The binding activities of alanine scanning mutants of heavy chain
(A) and light chain (B) were analyzed by ELISA. C, Quantitative
dissociation kinetics of indicated mutants were analyzed. HER2-ECD
protein was immobilized on a CM5 sensor chip followed by exposure
to indicated mutant Fab antibodies. 100% point was defined as the
response unit (RU) at 200 seconds from experiment start. Koff values
were calculated using the BIAevaluation software.
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values of alanine scanning mutants were analyzed using SPR against
immobilized HER2-ECD protein. We confirmed that heavy chain
G98A mutant completely lost binding activities, and the neighboring
T99HA and G97HA mutants resulted in 32-fold and 17-fold increased
koff values, respectively (Fig. 22C and 22D). These results indicate
that heavy chain Gly98H is functionally critical and its adjacent
residues are also functionally important for antigen-antibody
interaction.
Affinity maturation of hz1E11
Affinity maturation of hz1E11 was conducted by the construction of
heavy or light chain CDR3 randomized library, followed by the
equilibrium selection of phage antibody library. For light chain,
glutamine residues at position 89L and 90L were excluded because
they are commonly found in 9 amino acid length CDR-L3 at 59% and
73% frequencies, respectively (Martin, 1996). Positions 91L–94L were
randomized using NNK degenerated codon (L-NNK). For heavy
chain, positions 95H-100aH were randomized using XXS codon
(H-XXS), which were designed so that at the first and second
positions of the diversified codon the wild type base occurs with 70%
chance and each of the other three bases occur at 10% frequency,
and the third letters of the codons were synthesized using an
equimolar mixture of G and C (Fig. 23A). High affinity binders were
selected from high-stringency or low-stringency panning (Fig. 23B).
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Figure 23. Library design and panning strategy
A, For light chain, positions 91L–94L were randomized using NNK
degenerated codon (L-NNK). For heavy chain, positions 95H-100aH
were randomized using XXS codon (H-XXS) or twin NNS random
codon scanning of CDR-H3 (H-2AA). B, High affinity binders were
selected from high-stringency or low-stringency panning.
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Compared to the low-stringency panning in which 100% of the
second, third and fourth round output clones screened were ELISA
positive, for the high-stringency panning the fourth round output
yielded no binder at all, and only one third of the third round output
clones were ELISA positive (Table 1). The selected clones from the
CDR-L3 library included many sequences that had all four
randomized CDR-L3 positions mutated, unlike CDR-H3 libraries from
which most of the selected clones retained the wild type sequence in
positions 97H-100H (see below). Different panning strategies yielded
different sequence enrichment pattern: for example, the light chain
variant clone 1A12 (Q89LQNAYAPWT97L) was isolated from the
high-stringency panning but not from the low-stringency panning,
and the heavy chain variant clone 1B12 (N95HYGGTASFDY102H) was
selected only from the high-stringency panning. Interestingly, 59% of
unique antibodies in 4th output with low-stringency panning of
L-NNK library had an alanine at position 92L, in line with alanine
scanning analysis (Fig. 24A).
Almost all clones that were isolated from the H-XXS library had the
same sequence at 97H–100H as the parental clone, and showed a
clear enrichment of Asn-Tyr sequence at 95H–96H. To further assess
the contribution of CDR-H3 residues to antigen-antibody binding, we
constructed additional CDR-H3 library with twin NNS random codon
scanning of CDR-H3 (H-2AA). In low-stringency panning, mutants
at positions 95H, 96H, 99H, 100H, and 100aH were selected in first
round panning, but only mutants at positions 95H and 96H were
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Panning-1 73% 50% 20% 3% 2
nd
output NYGGTASFDY (8/9)HFGGTASFDY(1/9)



















Table 1. Panning results of CDR-L3 and CDR-H3 library
1) For diversity of L-NNK library with panning-2, only 4 enriched clones are presented. Substituted amino
acids are underlined.
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Figure 24. Sequence and binding properties of affinity-matured
clones
A, Sequence logo were generated using WebLogo program about
unique clones in 4th output of CDR-L3 library with low-stringency
panning (n = 39). B, The hz1E11 was immobilized on a CM5 sensor




enriched in 4th round output (Table 1). We could not detect the
mutants at positions Gly97H and Gly98H in any panning strategies and
outputs.
Affinity and binding activity of selected clones
To assess the combination effect of the affinity-matured heavy and
light variants, IgG antibodies with combinations of affinity-matured
heavy and light chains were produced and their koff values were
determine using SPR analysis (Table 2). Among two light chain
variants and two heavy chain variants, 1A12 derived from L-NNK
showed the highest improvement (16-fold). The combination of the
light chain of 1A12 with the optimized heavy chain variants improved
koff value such that the combination of 1A12 light chain and 1B12
heavy chain resulted in a 24-fold improvement in koff over the
parental hz1E11. Because the improvement by this combination was
not significantly large, clones 1A12 and 1F11 (light chain variants)
were chosen for further characterization to minimize the sequence
difference of the affinity-matured antibodies from the parental clone.
To determine whether affinity-matured hz1E11 clones bind to the
same epitope as hz1E11, the binding of 1A12 and 1F11 to the
HER2-ECD that was pre-bound to hz1E11 was analyzed by SPR.
Both clones were unable to bind to the monomeric HER2-ECD-His




hz1E11 QQLYSTPWT HLGGTASFDY 4.48E-4
L-1A12 QQNAYAPWT HLGGTASFDY 2.80E-5
L-1F11 QQTAFSPWT HLGGTASFDY 5.89E-5
H-1B12 QQLYSTPWT NYGGTASFDY 7.40E-5













Table 2. Koff measurement of selected clones
l Substituted amino acids are underlined.
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(Fig. 24B). This data indicate that epitopes of 1A12 and 1F11 does
not change by affinity maturation process.
Efficacy of affinity matured hz1E11 clones
Both 1A12 and 1F11 antibodies showed slightly increased
antiproliferative activities as a single agent compared to hz1E11 on
NCI-N87 and OE-19 gastric cancer cell lines that overexpress HER2
(Fig. 25A and 25B), whereas in combination with trastuzumab, their
antiproliferative activities was superior to that trastuzumab alone and
equivalent to hz1E11 plus trastuzumab. The antiproliferative activity
of 1A12 and 1F11 was confirmed in vivo in NCI-N87 and OE-19
xenograft models. They showed superior antitumor activity in
combination with trastuzumab to that of each agent alone in both
xenograft models (Fig. 26A and 26B).
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Figure 25. Affinity-matured hz1E11 clones shows
antiproliferative activity in HER2-overexpressing gastric cancer
models
A, NCI-N87 cells and B, OE-19 cells were treated with antibodies
for 4 days in the complete growth media. Data points of cell viability
assay are mean ± SD (n = 3) and the 100% point was defined as the
absorbance of antibody untreated well.
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Figure 26. Antitumor activity of affinity-matured hz1E11 clones
in xenograft models
A, NCI-N87 (n = 5 mice/group) and B, OE-19 (n = 6 mice/group)
cells were inoculated into mice and antibody treatments were started
when tumor volumes reached approximately 200 mm3. Mice received
a dose of 20 mg/kg for single agent treatment and 10 mg/kg of each
antibody for combination treatment. Administration days are indicated




Despite encouraging clinical results obtained with the HER2 targeting
antibody trastuzumab in the treatment of gastric cancer, it is still
necessary to develop the more potent HER2 targeted therapies (Bang
et al., 2010). Combination of non-competing antibodies targeting
receptors such as HER2, EGFR, and VEGFR3 can increase antitumor
activity in preclinical models (Kamat et al., 2008; Pedersen et al.,
2010; Tvorogov et al, 2010; and Zhang et al., 2010). Pertuzumab,
another HER2-targeting antibody, is approved for use in combination
with trastuzumab in the treatment of metastatic breast cancer
(Baselga et al., 2012). In the previous study, we developed a novel
HER2 targeting antibody, 1E11, which shows significant antitumor
activity as a single agent and synergistic effect in combination with
trastuzumab in in vitro and in vivo models (in press). The antitumor
activity of 1E11 and trastuzumab combination is superior not only to
trastuzumab single treatment but also to the combination of
pertuzumab and trastuzumab. In this report, the humanization and
subsequent affinity maturation of the mouse hybridoma-derived 1E11
monoclonal antibody is described.
Initial approaches to reduce potential immunogenicity of nonhuman
variable regions by CDR-grafting into a human framework
significantly decreased the immunogenicity of therapeutic antibodies
(Jones et al., 1986 and Hwang and Foote, 2005). The
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superhumanization using human germline frameworks as template has
been proposed as a superior humanization methodology to avoid
putative effector T-cell epitopes derived by somatic hypermuations of
human framework (Tan et al., 2002; Hwang et al., 2005; Pelat et al.,
2008). It has been suggested that antibodies encoded by germline
gene segments are structurally flexible and able to accommodate
binding to many different antigens (James et al., 2003; Wong et al.,
2011; Yin et al., 2003). The CDRs of murine antibody 1E11 as well
as one residue in the Vernier zone of VH (Ala49H) were grafted on to
the human germline variable and joining genes with highest
homology to the parental antibody (Fig. 19). The resulting humanized
antibody, hz1E11, shows almost identical affinity (Fig. 20) and
biological activity to the parental antibody (Fig. 21).
Selection of residues for randomization is a critical step in targeted
randomization approach of affinity maturation because of the practical
limitations of antibody library size and the selection technologies.
Alanine scanning and in silico analysis of the antibody sequence,
especially in CDRs, are useful for selecting the randomization target
residues and facilitate the affinity maturation process. In alanine
scanning analysis of CDR-H3 of hz1E11, G98HA mutant completely
lost binding activity, and G97HA and T99HA mutants showed reduced
binding activity (Fig. 22A). Direct alteration of an essential paratope
residue usually results in the total loss of binding ability of the
antibody (Cho et al., 2003; James et al., 2003; Kelley and O’Connell;
1993); therefore, a more conservative approach to CDR-H3
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randomization was employed, using either a “hand-mixed”
oligonucleotide that is biased toward the parental sequence, or the
twin NNS random codon scanning of CDR-H3. As expected from the
alanine scanning analysis, almost all clones that were isolated from
the CDR-H3 libraries had the sequence 97H–100aH same as the
parental clone (G97HGTAS100aH).
The alanine scanning results suggest that all CDR-L3 residues are
dispensable, although the mutation of Ser93L to alanine seems to
lower the affinity (Fig. 22B). Therefore, four positions of CDR-L3
(91L–94L) were fully randomized using NNK degenerate codon. The
sequence analysis of the selected clones confirms the results from the
alanine scanning analysis; the majority of the selected clones from
the CDR-L3 library had all four randomized CDR-L3 positions
changed from the parental residue, contrary to the CDR-H3
optimization results in which most of the selected clones from the
libraries have the same sequence as the parental hz1E11 in the
middle part of the CDR (Table 1). It is also noted that the clones
with most affinity improvement came from the CDR-L3 library. It is
probable that the CDR-H3 of hz1E11 is already close to optimal and
most mutations, especially in the region 97H–100H, are deleterious to
the binding affinity, while the CDR-L3 sequence is not as optimal
and the mutation in this region can result in significant improvement
in the affinity. The L-NNK library panning outputs were enriched
with clones with a hydrophobic amino acid at the position 91L, a
small amino acid at 92L, and an aromatic amino acid at 93L; this
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pattern is some what different from the parental CDR-L3 sequence of
Q89LQLYSTPWT97L and again suggests that the CDR-L3 sequence of
the parental 1E11 antibody was sub-optimal and had some
opportunity for affinity improvement.
The clones with most improvement in affinity, 1A12 and 1F11, came
from the high-stringency panning of the CDR-L3 NNK library,
although 1F11 was also found from the low-stringency panning of
the same library (Table 2). Compared to the low-stringency panning
in which 100% of the second, third and fourth round output clones
screened were ELISA positive, for the high-stringency panning the
fourth round output yielded no binder at all, and only one third of the
third round output clones were ELISA positive (Table 1). It is likely
that the extremely antigen-limiting condition favored clones with
higher affinity, however at the same time the low level of
non-specific binding of phage particles became more evident, and
even dominated the panning output. In agreement with this argument,
sequence analysis of the ELISA positive clones showed that the
high-stringency panning resulted in the convergence of the output
clones to a small number of sequences, while the sequences were
more divergent for the output clones from the low-stringency
panning. For the CDR-H3 libraries, the overall pattern of the panning
output titer and the ratio of ELISA positive clones were similar to
that of the CDR-L3 libraries; i.e. higher panning stringency had a
negative effect on both parameters. Not surprisingly, the highly
enriched clone (1B12) with CDR-H3 sequence N95HYGGTAS100aH had
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koff value that was more than 5 times slower than that of the
parental antibody. The combination of the VH of 1B12 and VL of
1A12 further improved koff and KD slightly.
The humanized, affinity matured anti-HER2 clones showed inhibitory
activity on the growth of HER2-positive gastric cancer cell lines in
vitro and in vivo xenograft models. The inhibitory activity does not
reflect the improvement in the binding affinity, however, and their
maximal growth inhibition and IC50 values are comparable to those of
the parental hz1E11, possibly because the hz1E11 already had
sufficiently high inhibitory activity on HER2-overexressing cancer cell
lines. Of course, this does not necessarily mean that they would have
similar clinical efficacies, and the effect of the affinity improvement of
hz1E11 on the growth of HER2-positive human tumors needs to be
evaluated in future development research.
To summarize, an anti-HER2 murine antibody 1E11 was humanized
and affinity matured through extensive library construction, panning,
and screening efforts. High-stringency, antigen-limiting selection
conditions facilitated the isolation of affinity matured clones, among
which the best ones were CDR-L3 variants. Different CDR
diversification strategies produced different sequence enrichment
patterns, with varying degrees of success in affinity improvement. On
the other hand, the stringency of panning had similar effects on the
output pattern for all the libraries. It is anticipated that these results
can be utilized to improve the experimental design of future affinity
114
maturation efforts and generate highly optimized antibody clones for
therapeutic and other applications.
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CONCLUSION
Gastric cancer is one of the leading types of cancer worldwide.
Although the trend in death rates for gastric cancer is decreasing,
prognosis is poor and few therapeutic options are available,
particularly in advanced stages. HER2 is a type 1 transmembrane
receptor tyrosine kinase (RTK) and member of the epidermal growth
factor receptor (EGFR/ErbB) family and it induces the transduction of
signaling via two major pathways, which are the Ras/Raf/MEK/ERK
and the PI3K/AKT/mTOR pathways. And these pathways promote
cell proliferation, inhibition of apoptosis, angiogenesis, and invasion
which leading to tumor growth and progression. The frequency of
HER2-positive gastric cancer is 22.1% based on ToGA trial.
Trastuzumab, trade name HERCEPTIN, is HER2-targeting therapeutic
antibody and approved for the treatment of HER2-overexpressing
metastatic gastric cancer based on ToGA trial. Recent evidence
suggests that particular combinations of noncompetitive antibodies
targeting the same receptor increase antitumor activity in vitro and in
vivo.
In this study, I demonstrate that 1E11 shows significant antitumor
activity as single agent in in vitro and in vivo HER2-positive gastric
cancer models. Antitumor activity of 1E11 is increased in a highly
synergistic manner in combination with trastuzumab. The two
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antibodies bind to sub-domain IV of the receptor, but have
non-overlapping epitopes, allowing them to simultaneously bind HER2.
Treatment with 1E11 alone induced apoptosis in HER2-positive
cancer cells, and this effect was enhanced by combination treatment
with trastuzumab. Combination treatment with 1E11 and trastuzumab
reduced the levels of total HER2 protein and those of aberrant HER2
signaling molecules including phosphorylated HER3 and EGFR. 1E11
was further optimized to reduce the immunogenicity and to increase
the affinity through humanization and affinity maturation. I selected
1A12 clone which has 4 amino acid mutations in CDR-L3 and
showed its improved affinity against HER2 protein more than 10-fold.
I confirm that antitumor activity of 1A12 is correlated with HER2
levels in more than 15 gastric and breast cancer cell panel. The
antibody-dependent cellular cytotoxicity (ADCC) activity of 1A12 is
comparable to that of trastuzumab and pertuzumab. In combination
setting with trastuzumab, 1E11 completely inhibits tumor growth in
OE-19 xenograft model, while pertuzumab causes partial inhibition of
tumor growth. Taken together, I propose that combination treatment
of 1A12 and trastuzumab could be a novel potent therapeutic strategy
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본 연구에서는 HER2 를 표적하며 HER2 과발현 위암에서 단독으로
항암 효능을 보일뿐 아니라 trastuzumab 과 병용처리 시 동반
상승효과를 보이는 신규 항체의 효능, 작용기전, 항체 최적화에 대한
연구가 수행되었다.
위암은 세계적으로 많은 발생빈도를 보이는 암이다. 위암에 의한
사망률이 점차 낮아지는 추세이긴 하지만, 예후가 좋지 않고 적절한
치료 방법이 없는 상태이다. HER2 는 세포막 수용체 타이로신
인산화효소 (receptor tyrosine kinase, RTK)로 EGFR/ErbB (epidermal
growth factor receptor) family 에 속하며, HER2 이외에도 EGFR,
HER3, HER4 단백질들이 속해있다. ErbB 단백질들은 리간드와
결합하는 세포외 도메인, 세포투과 도메인, 세포내 도메인으로 구성되어
있다. HER2 를 제외한 ErbB 단백질들은 접힌 상태로 되어 이합체화를
유도하는 서브도메인 II (sub-domain II)가 숨겨져 있는 상태로
존재한다. HER2 의 주요 신호전달계는 Ras/Raf/MEK/ERK와
PI3K/AKT/mTOR이며, HER2 는 이들 신호전달계를 통하여 암의 성장
및 진행과 관련된 세포 증식, 세포 사멸 억제, 혈관생성, 세포이동 등을
유도한다.
HER2 단백질의 과발현은 위암 환자의 22.1%에서 관찰됨이 ToGA
임상시험을 통하여 확인되었다. HER2 과발현과 위암의 예후와의
상관관계에 대해서는 모순되는 보고가 있으나, 많은 연구들이
상관관계가 있음을 보고하고 있다. Trastuzumab (제품명
146
HERCEPTIN)은 HER2 를 표적하는 항체로 HER2 과발현 유방암에 대한
치료제이며 최근에는 HER2 과발현 전이성 위암에 대한 치료제로도
승인받았다. ToGA 임상시험에 따르면 trastuzumab 처리와 화학요법을
병용시행 시 평균 전체 생존율이 13.8 개월로 화학요법만 시행한 경우인
11.1개월 보다 향상되었다. Trastuzumab 이 임상적 효능을 보이고는
있지만 보다 향상된 효능을 보이는 치료법의 개발이 필요하다. 최근
동일 단백질을 표적하는 항체들의 병용처리에 의한 항체치료 효능의
향상이 보고되고 있다. 대표적인 예인 pertuzumab 은 HER2 를 표적하는
항체로, trastuzumab 이 서브도메인 IV에 결합하는 반면 pertuzumab 은
서브도메인 II 에 결합한다. Pertuzumab 은 단독으로는 항암 효능이
미비하지만 trastuzumab 과 병용처리하면 각 항체를 단독 처리한
경우보다 향상된 효능을 보인다. 이와 같은 병용처리의 예는 EGFR과
VEGFR3 를 표적하는 항체들에 대해서도 보고되었다.
본 연구에서는 HER2 를 표적하는 신규 단클론항체인 1E11 의 효능과
작용기전을 HER2 과발현 위암과 유방암을 대상으로 수행되었다.
1E11 은 HER2 과발현 위암의 in vitro 및 in vivo 모델에서 단독으로도
의미 있는 항암 효능을 보일뿐만 아니라 trastuzumab 과 병용투여 시에
동반 상승효과를 보였다. 두 항체 모두 서브도메인 IV에 결합하지만
서로 epitope 를 공유하지 않기 때문에 HER2 에 동시에 결합하였다.
1E11 항체는 단독으로 HER2 과발현 암의 세포사멸을 유도하였으며,
이런 활성은 trastuzumab 과 병용처리 시에 상승하였다. 1E11 과
trastuzumab 을 동시처리 시에 전체 HER2 단백질이 감소하였으며
인산화된 형태의 EGFR과 HER3 의 양도 감소되었다. 1E11 는 생쥐
유래 항체이기 때문에 인간에 투여 시 가변영역에 대한 면역반응이
유도될 수 있다. 이를 극복하기 위해서 인간 germline 항체를 골격으로
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한 항체에 상보성결정지역을 이식하는 방법으로 인간화 항체를
개발하였다. 이렇게 개발된 인간화 항체인 hz1E11 은 1E11 과 동등한
친화도와 생물학적 활성을 보였다. 또한 hz1E11 의 친화도 향상을
위해서 중쇄사슬 및 경쇄사슬의 상보성결정지역 3 에 다양성을 부여하고
파지디스플레이 (phage display) 기술을 이용하여 친화도가 향상된
항체를 선별하였다. 선별된 1A12 항체는 경쇄사슬의 상보성결정지역
3 에 4개의 아미노산이 변형된 항체로 10배 이상 HER2 단백질에 대한
친화도가 향상된 항체이다. 그리고 1A12 의 항암 활성이 HER2 의 발현
정도와 관련이 있음을 15개 이상의 위암 및 유방암 세포를 대상으로
확인하였다. 또한 1A12 항체가 trastuzumab 이나 pertuzumab 과 동등한
항체의존 세포독성을 보임을 확인하였다. Trastuzumab 과 병용처리
시에 1A12 는 OE-19 세포를 이용한 이종이식 모델에서 암의 성장을
완전히 억제한 반면 pertuzumab 은 암의 성장을 다소 억제하는데
그쳤다.
결과적으로 1E11 은 trastuzumab 과 병용처리 시에 HER2 과발현 위암의
억제에 동반 상승효과를 보였다. 1E11 의 항암효능은 세포사멸 유도 및
HER2 세포신호전달계 억제를 통하여 나타난다. 따라서 이들 항체의
병용처리는 HER2 과발현 위암 환자에 대한 새로운 치료제로서 높은
가능성을 갖고 있다.
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